Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Headquartered in Hamilton, Bermuda, Kiniksa is at the forefront of developing immune-modulating assets aimed at addressing a spectrum of cardiovascular and autoimmune conditions.
The company’s clinical-stage product candidates include:
- ARCALYST (rilonacept): The first and only FDA-approved therapy for recurrent pericarditis, a debilitating inflammatory cardiovascular disease. ARCALYST is also approved for cryopyrin-associated periodic syndromes (CAPS) and deficiency of IL-1 receptor antagonist (DIRA).
- Mavrilimumab: An investigational monoclonal antibody targeting the GM-CSF receptor, currently being evaluated for its potential in treating giant cell arteritis and other rare cardiovascular diseases.
- Vixarelimab: An investigational monoclonal antibody inhibitor of signaling through OSMRβ.
- Abiprubart (formerly KPL-404): A humanized monoclonal antibody designed to inhibit the CD40-CD154 interaction, aimed at treating autoimmune diseases such as rheumatoid arthritis and Sjogren’s Disease.
Kiniksa’s robust pipeline is supported by significant financial strength. The company reported strong revenue growth with ARCALYST, achieving net product revenue of approximately $233.1 million in 2023, a 90% year-over-year increase. This financial performance provides a solid foundation for future investments in both commercial and clinical development projects.
Recent news highlights Kiniksa’s progress:
- In July 2023, Kiniksa announced plans to raise its 2023 ARCALYST sales guidance to between $220 million and $230 million, citing increased prescriber adoption and patient enrollments.
- In October 2023, the company reported third-quarter financial results and the completion of enrollment in the third cohort of the Phase 2 trial of KPL-404 in rheumatoid arthritis, with data expected in the first quarter of 2024.
- In February 2024, Kiniksa announced its plans to initiate a Phase 2b trial of abiprubart in Sjogren’s Disease in the second half of 2024, supported by robust ARCALYST revenue growth and a strong cash position.
For more information about Kiniksa and its pipeline, visit www.kiniksa.com.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Interested individuals can register for telephone participation, and upon registration, will receive confirmation details including a unique passcode and registrant ID. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.
Kiniksa Pharmaceuticals has begun enrolling patients in a Phase 2b clinical trial for abiprubart, a humanized anti-CD40 monoclonal antibody, aimed at treating Sjögren’s Disease, a debilitating autoimmune disorder. The trial will assess the efficacy of abiprubart administered biweekly and monthly via subcutaneous injections over a 24-week period, involving around 201 participants. The primary measure of success is the change in the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) compared to a placebo. The study will also include a long-term extension phase where all participants receive active treatment. Importantly, Kiniksa expects to remain cash flow positive during this development.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced a partnership with NHL Hall-of-Famer Henrik Lundqvist to raise awareness about recurrent pericarditis. This campaign, starting in September, aims to share experiences from the recurrent pericarditis community and provide resources for patients and caregivers. Recurrent pericarditis is characterized by severe inflammation of the pericardial tissue, leading to sharp chest pain often mistaken for a heart attack. The disease significantly impacts patients' quality of life and physical wellbeing. CEO Sanj K. Patel emphasized the need for increased disease understanding to prevent delayed diagnosis and treatment. More information can be found at whatispericarditis.com and arcalyst.com.
Kiniksa Pharmaceuticals announced its sponsorship of the American Heart Association's Addressing Recurrent Pericarditis initiative on June 17, 2024. This initiative aims to enhance care for recurrent pericarditis patients through improved diagnosis and treatment practices. The program will involve healthcare champions at 15 sites to identify gaps and share best practices nationwide. The initiative aims to improve patient outcomes and quality of life through education, model sharing, and collaborative research. Key sites involved include Brigham & Women’s Hospital, Cleveland Clinic, and Mayo Clinic.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced its management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for Tuesday, June 11, 2024, at 8:40 a.m. Eastern Time.
The presentation will be live-streamed on Kiniksa's website under the Investors & Media section. A replay will be available approximately 48 hours post-event.
Kiniksa Pharmaceuticals, (Nasdaq: KNSA) will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on May 14, 2024. The presentation will be available via webcast on the company's website.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is Kiniksa Pharmaceuticals' primary focus?
What are the key products in Kiniksa's pipeline?
What recent achievements has Kiniksa Pharmaceuticals reported?
What is ARCALYST used for?
When was Kiniksa's latest financial report released?
What is the expected revenue for ARCALYST in 2024?
What is abiprubart (KPL-404) targeting?
What are some of the conditions Kiniksa is targeting with its therapies?
Where can I find more information about Kiniksa Pharmaceuticals?
Who should be contacted for investor and media inquiries?
